Company Overview
Indivior Pharmaceuticals, Inc. engages in the development, manufacture, and sale of buprenorphine-based prescription drugs designed for the treatment of opioid dependence and related disorders across the United States, Europe, Canada, Australia, and other international markets. The company operates within the Healthcare sector, specifically functioning in the Drug Manufacturers - Specialty & Generic industry, which focuses on producing pharmaceuticals for specialized therapeutic areas rather than broad consumer markets. As a significant entity in its field, the company maintains a market capitalization of $3.81B and employs 827 individuals to support its global operational footprint. The annual revenue reported over the trailing twelve months stands at $1.24B, figures that collectively indicate the company holds a substantial position as a specialized player in the global pharmaceutical landscape with a multi-billion dollar valuation.
Financial Health
The company reported a trailing twelve-month revenue of $1.24B, generating a net income of $210.00M and an EBITDA of $397.00M, a spread that reveals a robust cost structure where operating expenses consume less than half of the gross earnings before interest, taxes, depreciation, and amortization. Free cash flow for the period reached $221.75M, providing the organization with significant financial flexibility to fund ongoing research and development, manage capital expenditures, or potentially reduce leverage without immediate reliance on external financing. Profitability is highlighted by a gross margin of 84.0%, an operating margin of 37.2%, and a profit margin of 16.9%, demonstrating that the high-margin nature of specialty drug manufacturing allows the firm to retain a significant portion of sales revenue after covering the substantial costs associated with bringing drugs to market. The company holds $195.00M in cash against $351.00M in total debt, resulting in a debt-to-equity ratio that is listed as N/A, suggesting a balance sheet that is leveraged but supported by strong cash generation capabilities rather than heavy equity dilution. Liquidity analysis shows a current ratio of 0.71, indicating that current liabilities exceed current assets, which suggests the company relies heavily on its operating cash flow to meet short-term obligations rather than holding a large buffer of liquid assets. Return on equity is listed as N/A, while return on assets stands at 19.2%, a metric that reveals management is effectively utilizing the company's asset base to generate nearly 20% in pre-tax returns relative to the total assets employed.
Valuation Assessment
Valuation metrics show a P/E ratio (TTM) of 18.60 compared to a forward P/E of 8.86, implying that the market expects earnings to grow significantly in the coming year, as the forward multiple is less than half the trailing multiple. The price-to-book ratio is reported as -38.90, a negative figure indicating that the market capitalization exceeds the book value of shareholders' equity, which suggests the market is pricing in significant intangible assets, brand value, or future growth potential that is not reflected in the accounting book value. Alternative valuation measures include a price-to-sales ratio of 3.08 and an EV/EBITDA of 10.00, metrics that suggest the company is valued at approximately three times its sales and ten times its earnings before interest, taxes, depreciation, and amortization, reflecting a premium often seen in healthcare companies with strong intellectual property portfolios. Regarding price action, the stock has traded between a 52-week high of $38.00 and a 52-week low of $8.64, placing the current trading range within a wide band that reflects high volatility and significant price discovery. The beta value is 1.19, meaning the stock's price volatility is 19% higher than the broader market, indicating that the stock will likely experience more pronounced swings during market upturns and downturns compared to the average large-cap stock.
Growth & Income
Growth dynamics are characterized by a revenue growth rate of 19.7% year-over-year and an earnings growth rate of 376.2% year-over-year, indicating that earnings are expanding at a rate vastly faster than revenue, which often implies one-time gains, exceptional expense reductions, or significant leverage effects on the income statement. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, meaning the firm reinvests all generated earnings back into the business to fuel research, development, and market expansion rather than distributing cash to shareholders. This reinvestment strategy aligns with the capital-intensive nature of pharmaceutical development and the need to sustain a pipeline of buprenorphine-based treatments. The overall growth and income profile presents a high-growth trajectory driven by substantial earnings expansion, supported by a lack of dividend obligations and a valuation structure that reflects high expectations for future profitability.